Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Jens Lutz, Kerstin Jurk & Helmut Schinzel. (2017) Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. International Journal of Nephrology and Renovascular Disease 10, pages 135-143.
Read now
Read now
Anouk J. W. Gulpen, Arina J. Ten Cate-Hoek & Hugo Ten Cate. (2016) Upstream versus downstream thrombin inhibition. Expert Review of Cardiovascular Therapy 14:11, pages 1273-1282.
Read now
Read now
Edith A Nutescu. (2013) Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. Expert Opinion on Pharmacotherapy 14:4, pages 525-534.
Read now
Read now
Jeremy P. Berman & Jonathan L. Halperin. (2013) Novel Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation. Hospital Practice 41:1, pages 37-48.
Read now
Read now
Charles Mahan & Alex C. Spyropoulos. (2012) Improving prevention and treatment of venous thromboembolism: clinical trial results. Journal of Medical Economics 15:4, pages 611-622.
Read now
Read now
Raffaele De Caterina. (2011) Clinical experience with apixaban in atrial fibrillation: implications of AVERROES. Research Reports in Clinical Cardiology 2, pages 83-86.
Read now
Read now
Keren Borensztajn & C Arnold Spek. (2011) Blood coagulation factor Xa as an emerging drug target. Expert Opinion on Therapeutic Targets 15:3, pages 341-349.
Read now
Read now
Walter P Jeske, Jawed Fareed, Debra A Hoppensteadt, Bruce Lewis & Jeanine M Walenga. (2010) Pharmacology of argatroban. Expert Review of Hematology 3:5, pages 527-539.
Read now
Read now
Articles from other publishers (46)
Gianluca Grimaldi, Domenica Ancona, Domenico Tricarico, Paolo Stella, Cataldo Procacci, Antonio Germinario, Vito Bavaro, Vito Montanaro & Alessandro Delle Donne. (2021) Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. Pharmaceutics 13:2, pages 252.
Crossref
Crossref
Filipa Gouveia, Joana Bicker, Joana Gonçalves, Gilberto Alves, Amílcar Falcão & Ana Fortuna. (2019) Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review. Analytica Chimica Acta 1076, pages 18-31.
Crossref
Crossref
Maki Komiyama, Yusuke Miyazaki, Hiromichi Wada, Moritake Iguchi, Mitsuru Abe, Hisashi Ogawa, Masaharu Akao, Hajime Yamakage, Noriko Satoh-Asahara, Yoichi Sunagawa, Tatsuya Morimoto & Koji Hasegawa. (2018) A study on indices of apixaban anticoagulation: A single-center prospective study. Journal of Pharmacological Sciences 137:2, pages 105-109.
Crossref
Crossref
Alessandro Di Minno, Beatrice Frigerio, Gaia Spadarella, Alessio Ravani, Daniela Sansaro, Mauro Amato, Joseph P. Kitzmiller, Mauro Pepi, Elena Tremoli & Damiano Baldassarre. (2017) Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Reviews 31:4, pages 193-203.
Crossref
Crossref
Kathleen Quinn, Alistair John Ingram & Robert Glen Hart. 2015. Cardio-Renal Clinical Challenges. Cardio-Renal Clinical Challenges
29
39
.
A. Jalota, T. M. Scarabelli, L. Saravolatz, M. U. Bakhsh, P. Agrawal, R. Jalota, C. Chen-Scarabelli, V. Fuster & J. Halperin. (2014) Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. Cardiovascular Drugs and Therapy 28:3, pages 247-262.
Crossref
Crossref
Larry R. Jackson & Richard C. Becker. (2013) Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. Journal of Thrombosis and Thrombolysis 37:3, pages 380-391.
Crossref
Crossref
Emer R. McGrath, John W. Eikelboom, Moira K. Kapral & Martin J. O'Donnell. (2013) Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. International Journal of Stroke 9:1, pages 71-78.
Crossref
Crossref
Pedram Kazemian & Bodh I. Jugdutt. 2014. Aging and Heart Failure. Aging and Heart Failure
65
84
.
Thaddaus Hellwig & Michael Gulseth. (2013) Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants. Annals of Pharmacotherapy 47:11, pages 1478-1487.
Crossref
Crossref
Emine Gazi, Ahmet Temiz, Ahmet Barutcu & Yucel Colkesen. (2013) Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Drug Development Research 74:7, pages 485-491.
Crossref
Crossref
Meganathan Chandrasekaran, Sugunadevi Sakkiah & Keun Woo Lee. (2011) Combined chemical feature-based assessment and Bayesian model studies to identify potential inhibitors for Factor Xa. Medicinal Chemistry Research 21:12, pages 4083-4099.
Crossref
Crossref
Raffaele De Caterina & Giulia Renda. 2012. Therapeutic Advances in Thrombosis. Therapeutic Advances in Thrombosis
285
305
.
Graeme J. Hankey. (2012) Anticoagulant therapy for patients with ischaemic stroke. Nature Reviews Neurology 8:6, pages 319-328.
Crossref
Crossref
Kenneth A. Bauer. (2012) Reversal of antithrombotic agents. American Journal of Hematology 87:S1.
Crossref
Crossref
Paolo Prandoni. (2012) Healthcare burden associated with the post‐thrombotic syndrome and potential impact of the new oral anticoagulants. European Journal of Haematology 88:3, pages 185-194.
Crossref
Crossref
J.-P. Bassand. (2012) Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace 14:3, pages 312-324.
Crossref
Crossref
Joey S.W. Kwong & Yat-Yin Lam. (2012) Updates on new oral anticoagulants and percutaneous devices for stroke prevention in patients with non-valvular atrial fibrillation. International Journal of Cardiology 155:2, pages 340-341.
Crossref
Crossref
Jawed FareedIndermohan Thethi & Debra Hoppensteadt. (2012) Old Versus New Oral Anticoagulants: Focus on Pharmacology. Annual Review of Pharmacology and Toxicology 52:1, pages 79-99.
Crossref
Crossref
Rupert M. Bauersachs. (2012) Use of anticoagulants in elderly patients. Thrombosis Research 129:2, pages 107-115.
Crossref
Crossref
Richard J. Friedman. 2012. Insall & Scott Surgery of the Knee. Insall & Scott Surgery of the Knee
e142-1
e142-7
.
Benjamin Brenner & Ron Hoffman. (2011) Emerging options in the treatment of deep vein thrombosis and pulmonary embolism. Blood Reviews 25:5, pages 215-221.
Crossref
Crossref
Nadia Rosencher, Paul Zufferey, Silvy Laporte & Patrick Mismetti. (2011) Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders. Clinical Investigation 1:5, pages 725-737.
Crossref
Crossref
Bénédicte Dumont, Dorothée Faille & Nadine Ajzenberg. (2011) Les nouveaux anticoagulants oraux. médecine/sciences 27:5, pages 493-500.
Crossref
Crossref
Thomas Mavrakanas & Henri Bounameaux. (2011) The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacology & Therapeutics 130:1, pages 46-58.
Crossref
Crossref
Edith Nutescu, Ittiporn Chuatrisorn & Erika Hellenbart. (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. Journal of Thrombosis and Thrombolysis 31:3, pages 326-343.
Crossref
Crossref
Margareta Blombäck, Shu He, Niklas Bark, Håkan N. Wallen & Margareta Elg. (2011) Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*. British Journal of Haematology 152:6, pages 758-765.
Crossref
Crossref
Yu‐Kai Lee & Mark R. Player. (2011) Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Medicinal Research Reviews 31:2, pages 202-283.
Crossref
Crossref
Masayuki HASHIGUCHI & Mayumi MOCHIZUKI. (2011) 2. Pharmacokinetics and Drug Interaction of New Anticoagulants: Direct Thrombin Inhibitor and Factor Xa Inhibitors. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 42:5, pages 305-313.
Crossref
Crossref
Satoshi Ogawa, Yukito Shinohara & Kazuhiro Kanmuri. (2011) Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation. Circulation Journal 75:8, pages 1852-1859.
Crossref
Crossref
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza & Frank Misselwitz. (2010) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Reviews Drug Discovery 10:1, pages 61-75.
Crossref
Crossref
Jack Ansell. (2010) Warfarin Versus New Agents: Interpreting the Data. Hematology 2010:1, pages 221-228.
Crossref
Crossref
Mukesh Singh, Sasikanth Adigopula, Pawan Patel, Kranti Kiran & Sandeep Khosla. (2010) Recent advances in oral anticoagulation for atrial fibrillation. Therapeutic Advances in Cardiovascular Disease 4:6, pages 395-407.
Crossref
Crossref
Edelgard Lindhoff-Last, Meyer Michel Samama, Thomas L Ortel, Jeffrey I Weitz & Theodore E Spiro. (2010) Assays for Measuring Rivaroxaban: Their Suitability and Limitations. Therapeutic Drug Monitoring 32:6, pages 673-679.
Crossref
Crossref
H. Völler, S. Alban & D. Westermann. (2010) Neue orale AntikoagulanzienNew oral anticoagulants. Der Internist 51:12, pages 1571-1581.
Crossref
Crossref
Hans-Juergen Rupprecht & Ralf Blank. (2010) Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors. Drugs, pages 1.
Crossref
Crossref
Donald J. P. Pinto, Joanne M. Smallheer, Daniel L. Cheney, Robert M. Knabb & Ruth R. Wexler. (2010) Factor Xa Inhibitors: Next-Generation Antithrombotic Agents. Journal of Medicinal Chemistry 53:17, pages 6243-6274.
Crossref
Crossref
Ji Zhang & Jason Crawford. 2010. Modern Drug Synthesis. Modern Drug Synthesis
191
205
.
Pamela J. White. (2010) Patient Factors That Influence Warfarin Dose Response. Journal of Pharmacy Practice 23:3, pages 194-204.
Crossref
Crossref
John W. Eikelboom, Martin O'Donnell, Salim Yusuf, Rafael Diaz, Greg Flaker, Robert Hart, Stefan Hohnloser, Campbell Joyner, Jack Lawrence, Prem Pais, Janice Pogue, David Synhorst & Stuart J. Connolly. (2010) Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. American Heart Journal 159:3, pages 348-353.e1.
Crossref
Crossref
Mimi L. Quan, Donald J.P. Pinto, Karen A. Rossi, Steven Sheriff, Richard S. Alexander, Eugene Amparo, Kevin Kish, Robert M. Knabb, Joseph M. Luettgen, Paul Morin, Angela Smallwood, Francis J. Woerner & Ruth R. Wexler. (2010) Phenyltriazolinones as potent factor Xa inhibitors. Bioorganic & Medicinal Chemistry Letters 20:4, pages 1373-1377.
Crossref
Crossref
Richard J. Friedman. (2010) New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty. Thrombosis 2010, pages 1-9.
Crossref
Crossref
S. Charbonneau, H.T. Peng, P.N. Shek & M.D. Blostein. (2010) Amphipathic peptides can act as an anticoagulant by competing with phospholipid membranes for blood coagulation factors. Biochemical and Biophysical Research Communications 391:2, pages 1197-1202.
Crossref
Crossref
Jennifer Carreiro Zikria & Jack Ansell. (2009) Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Current Opinion in Hematology 16:5, pages 347-356.
Crossref
Crossref
Matthias Orth. (2009) Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. LaboratoriumsMedizin 33:2, pages 121-127.
Crossref
Crossref
Joanne M. Smallheer & Mimi L. Quan. 2009. Annual Reports in Medicinal Chemistry Volume 44. Annual Reports in Medicinal Chemistry Volume 44
189
208
.